Navigation Links
Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System

PALO ALTO, Calif., Feb. 12 /PRNewswire/ -- Nfocus Neuromedical, Inc. today announced that the company has received CE mark approval for the CardioVasc(TM) Stent-Graft and Delivery System. The CardioVasc(TM) Stent-Graft is a minimally invasive device for treating patients with Saphenous Vein Graft Lesions (SVGs) from a previous coronary bypass, Vessel Perforations and Coronary Artery Aneurysms. The CE mark allows Nfocus to begin marketing the CardioVasc(TM) Stent-Graft in the European Union, and indicates that the product complies with the appropriate quality and safety standards.

"We are pleased to be able to offer this valuable option to physicians in the European Union for treating diseased bypass grafts. This is an important first step in what we hope to be a series of regulatory approvals in the coming year," said Martin Dieck, President and CEO of Nfocus Neuromedical, Inc.

Saphenous Vein Graft Disease

Saphenous vein graft (SVG) disease has been a problem facing the cardiologist since the early days of coronary artery bypass graft (CABG) surgery. In CABG surgery, a segment of the patient's own leg vein (the "saphenous vein") may be removed and used to create an artificial conduit to bypass areas of blood flow blockage (also known as stenosis or plaque) that have built up in the patient's coronary artery. After CABG surgery, this SVG bypass itself may become blocked over time by the same type of disease that affected the patient's original coronary artery. The result is a need to reopen the diseased SVG vessel and restore flow. This second treatment again can be yet another surgery -- or alternatively, the SVG may be treated via angioplasty and stenting procedures using less-invasive endovascular (catheter) techniques. The CardioVasc(TM) Stent-Graft device is a permanent implant delivered via a less-invasive catheter procedure for patients that have a diseased SVG from a previous CABG surgery. The CardioVasc(TM) Stent-Graft is not approved in the United States.

Due to the large numbers of patients that have been helped by CABG surgery in past years, there is a large pool of patients with diseased SVG bypass vessels in need of this procedure.

For more information about Saphenous Vein Graft Disease see:

About Nfocus Neuromedical, Inc.

Nfocus is a neurovascular development, manufacturing and marketing company focused on treating hemorrhagic stroke. Current and future product programs are aimed at rapid treatment of aneurysms and fistulas in the brain. Nfocus also has developed the CardioVasc(TM) Stent-graft for specific applications within the coronary artery disease market. Based in Palo Alto, California, Nfocus is privately held and venture capital backed. See for further information.

SOURCE Nfocus Neuromedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... health professionals, announced today its affiliation with Tennessee Counseling Association. This ... the network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: ) , ... ,world firsts,: , TwinLink™ - the first ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: